{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:14:29Z","timestamp":1759335269842,"version":"build-2065373602"},"reference-count":5,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.jaad.2019.01.032","type":"journal-article","created":{"date-parts":[[2019,1,26]],"date-time":"2019-01-26T18:28:36Z","timestamp":1548527316000},"page":"276-278","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Pharmacy costs of medications for the treatment of onychomycosis in the United States"],"prefix":"10.1016","volume":"81","author":[{"given":"Eric J.","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shari R.","family":"Lipner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2019.01.032_bib1","article-title":"Part I: onychomycosis: clinical overview and diagnosis","author":"Lipner","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2019.01.032_bib2","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2165\/00019053-200119030-00005","article-title":"Cost of treatment for onychomycosis. Data from a 9-month observational study","volume":"19","author":"Stier","year":"2001","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"10.1016\/j.jaad.2019.01.032_bib3","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2165\/00019053-200119040-00007","article-title":"Cost effectiveness of continuous terbinafine compared with intermittent itraconazole in the treatment of dermatophyte toenail onychomycosis: an analysis of based on results from the L.I.ON. study. Lamisil versus itraconazole in onychomycosis","volume":"19","author":"Jansen","year":"2001","journal-title":"Pharmacoeconomics"},{"issue":"11","key":"10.1016\/j.jaad.2019.01.032_bib4","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1093\/cid\/cix634","article-title":"Trends in pricing and generic competition within the oral antibiotic drug market in the United States","volume":"65","author":"Alpern","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaad.2019.01.032_bib5","article-title":"Part II: Onychomycosis: treatment and prevention of recurrence","author":"Lipner","year":"2018","journal-title":"J Am Acad Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962219301380?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962219301380?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:50:57Z","timestamp":1759272657000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962219301380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":5,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S0190962219301380"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2019.01.032","relation":{},"ISSN":["0190-9622"],"issn-type":[{"type":"print","value":"0190-9622"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacy costs of medications for the treatment of onychomycosis in the United States","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2019.01.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}